Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343655 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Atorvastatin Treatment on Carotid Plaque.
A Phase 3 study, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Terminated
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
NCT00343655 is a Phase 3 study that was terminated before completion, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 160 participants.
The verdict
NCT00343655, a Phase 3 study, was terminated before completion, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the plaque in patients.
Interventions
- DRUG Atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343655
The ClinicalTrials.gov registry entry for NCT00343655 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atorvastatin is the first listed.
NCT00343655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343655 about?
NCT00343655 is a clinical study titled "Evaluation of Atorvastatin Treatment on Carotid Plaque.". The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the plaque in patients.
What is the current status of trial NCT00343655?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2007-01. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00343655?
The interventions under investigation include: Atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00343655?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.